NCT05596539 Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
| NCT ID | NCT05596539 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Hypophosphatasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2023-03-22 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2023-03-22 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess medical events during follow-up of adult patients having hypophosphatasia and consulting rheumatologists.
Eligibility Criteria
Inclusion Criteria: * men and women, * aged 18 and over, with no upper age limit, who have had a total alkaline phosphatase value of less than 40 IU/l on at least 3 occasions, or at least a total alkaline phosphatase value below 40 IU/L and evidence of ALPL gene polymorphism * with at least one rheumatological symptom. Exclusion Criteria: * transient hypophosphatasia: absence of confirmation of a value below 40 IU/l on at least 3 samples, lack of genetic confirmation * secondary hypophosphatasia according to the expert rheumatologist (drugs, endocrine disease, other genetic disease...).
Contact & Investigator
Christian ROUX, MD, PhD
STUDY DIRECTOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT05596539 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypophosphatasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05596539 currently recruiting?
Yes, NCT05596539 is actively recruiting participants. Contact the research team at christian.roux@aphp.fr for enrollment information.
Where is the NCT05596539 trial being conducted?
This trial is being conducted at Bordeaux, France, Lille, France, Lyon, France, Nice, France and 7 additional locations.
Who is sponsoring the NCT05596539 clinical trial?
NCT05596539 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Christian ROUX, MD, PhD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 130 participants.